Kinnate Biopharma Inc.
KNTE

$124.99 M
Marketcap
$2.65
Share price
Country
$-0.01
Change (1 day)
$7.19
Year High
$1.04
Year Low
Categories

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

marketcap

P/B ratio for Kinnate Biopharma Inc. (KNTE)

P/B ratio as of 2023: 0.69

According to Kinnate Biopharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.69. At the end of 2022 the company had a P/B ratio of 1.20.

P/B ratio history for Kinnate Biopharma Inc. from 2018 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 0.69
2022 1.20
2021 2.42
2020 4.40
2019 -96.71
2018 55.39